PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer
Wei Huang,1,* Zhengtao Qian,2,* Yuxin Shi,1,3,* Zheming Zhang,3 Rui Hou,1,3 Jie Mei,1,3 Junying Xu,1 Junli Ding1 1Department of Oncology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, 214023, People's Republic of China; 2Department of Cl...
Saved in:
Main Authors: | Huang W (Author), Qian Z (Author), Shi Y (Author), Zhang Z (Author), Hou R (Author), Mei J (Author), Xu J (Author), Ding J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Potential prognostic and immunotherapeutic value of calponin 1: A pan-cancer analysis
by: Hengli Zhou, et al.
Published: (2023) -
Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker
by: Pan Xie, et al.
Published: (2022) -
Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients
by: Wei Li, et al.
Published: (2022) -
Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer
by: Jin K, et al.
Published: (2015) -
Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers
by: Inga Hochnadel, et al.
Published: (2017)